Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Oct;8(5):908-12.
doi: 10.3748/wjg.v8.i5.908.

The immunotherapeutic effect of dendritic cells vaccine modified with interleukin-18 gene and tumor cell lysate on mice with pancreatic carcinoma

Zhao-Hui Tang  1 , Wen-Hong Qiu, Gao-Song Wu, Xiang-Ping Yang, Sheng-Quan Zou, Fa-Zu Qiu
Affiliations

The immunotherapeutic effect of dendritic cells vaccine modified with interleukin-18 gene and tumor cell lysate on mice with pancreatic carcinoma

Zhao-Hui Tang et al. World J Gastroenterol. 2002 Oct.

Abstract

Aim: To estimate the effect of a therapeutic vaccine against pancreatic carcinoma based on dendritic cell (DC) vaccine modified with tumor lysate and Interleukin-18 gene.

Methods: The BALB/C mice model of pancreatic carcinoma was induced with DMBA. DC vaccine was constructed through pulsed with tumor lysate and transfected by the recombinant adenoviral vector encoding IL-18 gene. The immunotherapeutic effects of DC vaccine on mice with pancreatic carcinoma were assessed (divided into DC-IL18-Lysate group, DC-Lysate group, DC-IL18 group, DC group, PBS group).

Results: After vaccination of the DC vaccine, the concentration of IL-18 and IFN-gamma were 2161+/-439 ng x L(-1) and 435+/-72 ng x L(-1) in DC-IL18-Lysate group and there was significant difference compared with other groups (P<0.01). After vaccination of the DC vaccine, the transplanted tumors were observed on 30 days in DC-Lysate groups, on 16 days in DC-IL18 groups, on 3 days in control group, but mice remained tumor-free for at least 50 days in DC-IL18-Lysate group and there was significant difference between DC-IL18-Lysate group and other groups (P<0.01). The median survival exceeds 62 days in DC-IL18-Lysate group. But the median survival was 48.6 days in DC-Lysate group, 33 days in DC-IL18 group, 17 days in PBS group. The survival period was obviously prolonged in DC-IL18-Lysate group than in other groups (P<0.05, P<0.01). The weight of pancreatic tumor was 0.22+/-0.083 g in DC-IL18-Lysate group, 1.45+/-0.74 g in DC-Lysate group, 1.89+/-1.34 g in DC-IL18 group, 3.0+/-1.6 g in DC group, 2.9+/-2.0 g in PBS group and the weight of tumor obviously reduced in DC-IL18-Lysate group than in other groups (P<0.05, P<0.01).

Conclusion: DC vaccine modified with tumor lysate and Interleukin-18 gene can induce a specific and effective immune response against pancreatic carcinoma cell.

PubMed Disclaimer

Figures

Figure 1
Figure 1
T cells were tested for cytolytic activity in a standard 4-h 51Cr-release assay. Effector-to target (E/T) ratio were from 20:1 to 100:1.
Figure 2
Figure 2
A, B The concentration of IL-18 and IFN-γ in the serum were measured by ELISA
Figure 3
Figure 3
The development of the transplanted tumors was observed in every day
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Motoi F, Sunamura M, Ding L, Duda DG, Yoshida Y, Zhang W, Matsuno S, Hamada H. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther. 2000;11:223–235. - PubMed
    1. Zhou ZH, Song MZ. Current therapies of pancreatic cancer. Shijie Huaren Xiaohua Zazhi. 2000;8:214–215.
    1. Liu JW, Li KZ. Pancreatic cancer, oncogene and anti oncogene. Shijie Huaren Xiaohua Zazhi. 2001;9:72–73.
    1. Zhang SN, Yuan SZ. Gene therapy for pancreatic carcinoma. Shijie Huaren Xiaohua Zazhi. 1999;7:269–270.
    1. Liu MP, Zhou JC, Guo XZ, Chen W, Dai B, An TY, Ma SY. Purification and characterization of antigen SC6 for pancreatic cancer. Shijie Huaren Xiaohua Zazhi. 1999;7:593–595.